.svg){kind=logo}
.svg){kind=icon}
MENU
CLOSE
MENU
CLOSE
Medicines Development for Global Health (MDGH) aims to bridge clinical research to healthcare policy and medicine access through investigating the use of moxidectin in communities affected by onchocerciasis.
In collaboration with national programs, healthcare providers, community leaders, and international stakeholders, MDGH is supporting the first implementation of moxidectin as an alternative treatment in onchocerciasis elimination programs.
In the Global Report on neglected tropical diseases (NTDs) published in 2023, the World Health Organization noted moxidectin’s efficiency as a microfilarial treatment against river blindness (onchocerciasis).
This new phase will assess moxidectin’s feasibility and safety in programmatic settings and its acceptance by communities. The impact of these factors on intervention effectiveness is well established. Local and international implementing partners will coordinate the community drug distribution.
By collaborating closely with local and international researchers, Medicines Development for Global Health aims to show community response to moxidectin to inform policy updates and future deployment of this new medicine against onchocerciasis.
Interaction with the respective National Drug Regulatory Agency to identify the authorization pathways for moxidectin use in the pilot project.
Social research to assess effectiveness of moxidectin introduction.
Communication tools for community sensitization and training materials for community drug distributors.
Delivery of moxidectin to country(ies). See below for more information.
Safety surveillance to ensure adequate serious adverse events / suspected adverse drug reaction monitoring.
Baseline and End-of-project surveys of community disease burden.
Led by the Kirby Institute - University of New South Wales Medicine & Health, Angola will host a cluster-randomised trial assessing the impact of moxidectin versus ivermectin mass drug administration on the prevalence of onchocerciasis and other neglected tropical diseases over 5 years. It is expected to start in 2025.
Under the Momentum project, the Ghana Health Service and partners will distribute moxidectin twice a year for 3 years in the district of Twifo Atti Morkwa. A social research study to confirm the operational feasibility of introducing moxidectin as an alternative treatment for onchocerciasis and its acceptability to the local population and stakeholders will be conducted by the University of Health and Allied Sciences (UHAS) and the Bruyere Research Institute, Canada. Educational materials are being developed to support community sensitization and training of the community distributors.
Follow our work by signing up for our newsletter
MDGH respectfully acknowledges the Traditional Owners of the land on which our office is located, the Wurundjeri people of the Kulin Nation, and pay our respect to their Elders past, present and emerging.
Medicines Development for Global Health Limited.
Level 1, 18 Kavanagh Street Southbank Victoria 3006 Australia.
ABN: 79 116 977 523
